Quarry LP Arcus Biosciences, Inc. Transaction History

Quarry LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$14.83 - $20.18 $25,952 - $35,315	1,750 Added 175.0%	2,750 $51.9 Million
Q4 2023 Feb 14, 2024	SELL	$13.43 - $19.63 $53,343 - $77,970	-3,972 Reduced 79.89%	1,000 $19.1 Million
Q3 2023 Nov 14, 2023	BUY	$17.62 - $23.54 $87,606 - $117,040	4,972 New	4,972 $89.2 Million

201

51.2M

288K

138K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $645M
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Quarry LP, based on Form 13F filings with the SEC.

Stay updated on Quarry LP with notifications on news.